Critical appraisal of selegiline transdermal system for major depressive disorder

References

• Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995 May;12(3):185–219. DOI:10.1016/0893-133X(94)00058-8.
   PubMed Web of Science ®Google Scholar
• Connolly KR, Thase ME. If at first you don’t succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs. 2011 Jan 1;71(1):43–64. DOI:10.2165/11587620-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Connolly KR, Thase ME. The clinical management of bipolar disorder: a review of evidence-based guidelines. Prim Care Companion CNS Disord. 2011;13(4). DOI:10.4088/PCC.10r01097.
   PubMedGoogle Scholar
• Stahl SM, Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr. 2008 Oct;13(10):855–870.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006 Nov;163(11):1905–1917. DOI:10.1176/ajp.2006.163.11.1905.
   PubMed Web of Science ®Google Scholar
• EMSAM - prescribing information [Internet]. 2007. [cited 2007 Jul 30]. Available from: http://www.emsam.com/~/media/C4C52F222B7A45B280C076D43FE3923A.ashx
   Google Scholar
• Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology. 1999 Mar;20(3):226–247. DOI:10.1016/S0893-133X(98)00075-X.
   PubMed Web of Science ®Google Scholar
• Somerset Pharmaceuticals Inc. EMSAM - selegiline transdermal system. Pychopharmacologic Drugs Advisory Committe NDA 21,336/21,708 2005. Available from: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4186b2_01_01_somerset-emsam.pdf
   Google Scholar
• Nandagopal JJ, DelBello MP. Selegiline transdermal system: a novel treatment option for major depressive disorder. Expert Opin Pharmacother. 2009 Jul;10(10):1665–1673. DOI:10.1517/14656560903048942.
   PubMed Web of Science ®Google Scholar
• VanDenBerg CM. The transdermal delivery system of monoamine oxidase inhibitors. J Clin Psychiatry. 2012;73(Suppl 1):25–30. DOI:10.4088/JCP.11096su1c.04.
   PubMedGoogle Scholar
• Magyar K. The pharmacology of selegiline. Int Rev Neurobiol. 2011;100:65–84. DOI:10.1016/B978-0-12-386467-3.00004-2.
   PubMed Web of Science ®Google Scholar
• Knoll J. The pharmacology of (-)deprenyl. J Neural Transm Suppl. 1986;22:75–89.
   PubMedGoogle Scholar
• Youdim MB. Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson’s disease. J Neural Transm Suppl. 1986;22:91–105.
   PubMedGoogle Scholar
• Palhagen S, Heinonen E, Hagglund J, et al. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology. 2006 Apr 25;66(8):1200–1206.
   PubMed Web of Science ®Google Scholar
• Mendis N, Pare CM, Sandler M, et al. Is the failure of (-)deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect? Psychopharmacology (Berl). 1981;73(1):87–90.
   PubMed Web of Science ®Google Scholar
• Quitkin FM, Liebowitz MR, Stewart JW, et al. l-deprenyl in atypical depressives. Arch Gen Psychiatry. 1984 Aug;41(8):777–781.
   PubMed Web of Science ®Google Scholar
• Mann JJ, Aarons SF, Wilner PJ, et al. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor. Arch Gen Psychiatry. 1989 Jan;46(1):45–50.
   PubMed Web of Science ®Google Scholar
• Sunderland T, Cohen RM, Molchan S, et al. High-dose selegiline in treatment-resistant older depressive patients. Arch Gen Psychiatry. 1994 Aug;51(8):607–615.
   PubMed Web of Science ®Google Scholar
• Wecker L, James S, Copeland N, et al. Transdermal selegiline: targeted effects on monoamine oxidases in the brain. Biol Psychiatry. 2003 Nov 15;54(10):1099–1104.
   PubMed Web of Science ®Google Scholar
• Azzaro AJ, Ziemniak J, Kemper E, et al. Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. J Clin Pharmacol. 2007 Oct;47(10):1256–1267. DOI:10.1177/0091270007304779.
   PubMed Web of Science ®Google Scholar
• Somerset Pharmaceuticals Inc. Adouble-blind, placebo-controlled, parallel assessment of the safety and efficacy of the selegiline transdermal system in patients with major depression. Tampa (FL): Somerset Pharmaceuticals Inc.; 2000. Protocol S9303-E106-96B.
   Google Scholar
• Somerset Pharmaceuticals Inc. A-double-blind, placebo-controlled, parallel assessment of the safety and efficacy of the selegiline transdermal system in patients with major depression. Tampa (FL): Somerset Pharmaceuticals Inc.; 2000. Protocol S9303-P9804.
   Google Scholar
• Somerset Pharmaceuticals Inc. A phaseIII flexible dose titration study of the safety and efficacy of the selegiline transdermal system in patients with major depression. Tampa (FL): Somerset Pharmaceuticals Inc. ; 2003. ProtocolS9303-P0052.
   Google Scholar
• Thase ME. The small specific effects of antidepressants in clinical trials: what do they mean to psychiatrists? Curr Psychiatry Rep. 2011 Dec;13(6):476–482. DOI:10.1007/s11920-011-0235-x.
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Bodkin JA. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. J Clin Psychopharmacol. 2006 Dec;26(6):579–586. DOI:10.1097/01.jcp.0000239794.37073.70.
   PubMed Web of Science ®Google Scholar
• Robinson DS, Gilmor ML, Yang Y, et al. Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials. Psychopharmacol Bull. 2007;40(3):15–28.
   PubMedGoogle Scholar
• Pae CU, Patkar AA, Jang S, et al. Efficacy and safety of selegiline transdermal system (STS) for the atypical subtype of major depressive disorder: pooled analysis of 5 short-term, placebo-controlled trials. CNS Spectr. 2014 Aug;19(4):324–329. DOI:10.1017/S1092852913000655.
   PubMed Web of Science ®Google Scholar
• Citrome L, Goldberg JF, Portland KB. Placing transdermal selegiline for major depressive disorder into clinical context: number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord. 2013 Nov;151(2):409–417. DOI:10.1016/j.jad.2013.06.027.
   PubMed Web of Science ®Google Scholar
• Cohen LJ, Sclar DA, Culpepper L, et al. Discussion: a fresh look at monoamine oxidase inhibitors for depression. J Clin Psychiatry. 2012;73(Suppl 1):42–45. DOI:10.4088/JCP.11096su1c.07.
   PubMedGoogle Scholar
• Azzaro AJ, Vandenberg CM, Blob LF, et al. Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects. J Clin Pharmacol. 2006 Aug;46(8:933–944. DOI:10.1177/0091270006289852.
   PubMed Web of Science ®Google Scholar
• Pae CU, Bodkin JA, Portland KB, et al. Safety of selegiline transdermal system in clinical practice: analysis of adverse events from postmarketing exposures. J Clin Psychiatry. 2012 May;73(5):661–668. DOI:10.4088/JCP.12m07648.
   PubMed Web of Science ®Google Scholar